Stockscreener 앱 받기
0.3672
3.29%
-0.0125
전일 마감가:
$0.3797
열려 있는:
$0.35
하루 거래량:
544.84K
Relative Volume:
0.02
시가총액:
$16.85M
수익:
-
순이익/손실:
$-23.74M
주가수익비율:
-0.091
EPS:
-4.0366
순현금흐름:
$-16.70M
1주 성능:
+6.35%
1개월 성능:
+65.33%
6개월 성능:
+28.37%
1년 성능:
-72.75%
1일 변동 폭
$0.35
$0.3672
1주일 범위
$0.3257
$0.3899
52주 변동 폭
$0.1628
$1.45
Theriva Biologics Inc Stock (TOVX) Company Profile
명칭
Theriva Biologics Inc
전화
301 417 4364
주소
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.3672 | 17.44M | 0 | -23.74M | -16.70M | -4.0366 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.22 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
798.92 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
302.01 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Theriva Biologics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
Theriva Biologics Reports FDA Alignment on VCN-01 Phase 3 Trial Design for Metastatic Pancreatic Cancer and Q1 2026 Financial Results - Minichart
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics: Q1 Earnings Snapshot - marketscreener.com
Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan
Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan
Theriva moves pancreatic cancer drug toward Phase 3, cash into 2027 - Stock Titan
TOVX Forecast, Price Target & Analyst Ratings | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
MSN Money - MSN
Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan
TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
TOVX|Theriva Biologics Inc|Price:0.330|Chg%:-0.03 - TradingKey
Theriva Biologics (TOVX) price target decreased by 42.86% to 4.08 - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Why is Theriva stock gaining Monday? - MSN
symbol__ Stock Quote Price and Forecast - CNN
TOVX Should I Buy - Intellectia AI
Press Releases about Theriva Biologics, Inc. Common Stock (NYSE:TOVX) - FinancialContent
Theriva Biologics posts 34.6% EPS beat, no revenueMeet Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Theriva Biologics announces pricing of $7.5M public offering - MSN
Theriva Biologics (TOVX) Comprehensive Review | Theriva Biologics posts 34.6% EPS beat, no revenueBorrow Rate - Cổng thông tin điện tử tỉnh Lào Cai
TOVX (Theriva Biologics Inc.) posts narrower than expected Q4 2025 loss, shares rise four percent on upbeat investor sentiment.Popular Trader Picks - Cổng thông tin điện tử Tỉnh Sơn La
Trending Stocks Today | Theriva Biologics Soars 67.92% Post-Market - 富途牛牛
BIOLASE Inc (BIOL) - Minichart
Theriva Biologics (NYSE: TOVX) asks shareholders to OK 16.18M warrant shares for $8.7M - Stock Titan
$Theriva Biologics (TOVX.US)$ keep loading on each pullback - Moomoo
Theriva Biologics stock surges on AACR cancer trial data - Investing.com
Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR - MEXC Exchange
Theriva Biologics stock surges on AACR cancer trial data By Investing.com - Investing.com UK
$Theriva Biologics (TOVX.US)$ it might be a miracle - Moomoo
Is Theriva Biologics (TOVX) stock breaking out today (Investors Pile In) 2026-04-20IPO Watch - Cổng thông tin điện tử tỉnh Lào Cai
Why Is Theriva Stock Gaining Monday? - Benzinga
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Data from AACR - MoneyCheck
Theriva Biologics (TOVX) Shares Soar 63% on Promising Pancreatic Cancer Trial Results - parameter.io
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial Results - Blockonomi
$Theriva Biologics (TOVX.US)$ added more to squeeze 🤞🏼🥳 - Moomoo
Theriva Biologics Presents Positive VIRAGE Phase 2b Clinical Trial Data of VCN-01 for Metastatic Pancreatic Cancer at AACR 2026 - Minichart
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 - GlobeNewswire Inc.
Theriva Biologics (TOVX) Set to Present New Clinical Data at AAC - GuruFocus
$Theriva Biologics (TOVX.US)$ sell too fast wow - Moomoo
Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data - TipRanks
[8-K] Theriva Biologics, Inc. Reports Material Event - Stock Titan
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - GlobeNewswire
CEO Moves: Is Theriva Biologics Inc subject to activist investor interest2026 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026 - Minichart
Theriva Biologics to reschedule stockholder meeting after lack of quorum By Investing.com - Investing.com Australia
Theriva Biologics to reschedule stockholder meeting after lack of quorum - Investing.com
Resistance Check: Is Theriva Biologics Inc in a long term uptrend2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Theriva Biologics Faces Delays in Warrant Approval Meeting - TipRanks
Theriva Bi Called Special Meeting Fails to Reach Quorum; Will Re‑call Meeting to Seek Approval for 16.18M Warrant Shares - TradingView
Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares - Stock Titan
Theriva Biologics Inc (TOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
2.09%
자본화:
|
볼륨(24시간):